Clinical Trials - Gastrointestinal Cancer

• CTSU – NCCTG- N0147 - A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) after Curative Resection for Patients with Stage III Colon Cancer

• ACOSOG  - Z 9001- A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec^TM) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST)-(Version 11/01/03)

• Phase III – Infusional 5-FU, Leucovorin, and Oxaliplatin (mFOLFOX6) every two weeks with bevacizumab (Avastin) to the same regimen without bevacizumab for the TX of resected Stage II and III Carcinoma of the Colon
  
  
• Gastrointestinal Stromal Tumors (GIST) Registry Protocol CST 15721BUS227
  
  
• PHASE II STUDY OF GW572016 (NSC #727989) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OR METASTATIC GASTRIC CANCER
  
  
• CTSU – CALGB 80405 - Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
  
  
• SWOG S0356 - Oxaliplatin Plus Protracted Infusional 5-Fluorouracil & Radiation For Potentially Curable Esophagus Cancer: Phase II Trial with Molecular Correlates.
  
  
• SWOG S0415 - Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer – Phase II